On the chances of Sun turning around Ranbaxy

A short piece on Sun's chances with reviving Ranbaxy. Most analysts I spoke to thought the valuation was too high for a company with so many regulatory problems. http://forbesindia.com/article/big-bet/sun-has-a-better-shot-than-most-at-ranbaxy-turnaround/37664/1

Fund crunch follows talent crunch at OSDD

This month, Forbes India published my article on how a talent crunch is hampering progress for India's open source drug discovery program. Yet, this program is very valuable in the training and exposure it provides to pharmaceutical researchers and the expertise it will create for the drug development industry, going forward. Sadly, soon after my article was published, there were news reports on OSDD running out of funds, because the cabinet did not sanction the earmarked funds in time. Now, OSDD has to wait till the elections are over for the funding cycle to start again. See Business World's report here:  http://www.businessworld.in/news/economy/funds-crunch-hits-india-s-drug-development-project/1319301/page-1.html . A pathetic state of affairs.

My article here: http://forbesindia.com/article/big-bet/the-collateral-benefits-of-indias-open-source-drug-discovery-programme/37514/1